Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Serious clinical events in HIV-positive persons with chronic kidney disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Léna G Dietrich
  • Catalina Barceló
  • Christian W Thorball
  • Lene Ryom
  • Felix Burkhalter
  • Barbara Hasse
  • Hansjakob Furrer
  • Maja Weisser
  • Ana Steffen
  • Enos Bernasconi
  • Matthias Cavassini
  • Sophie de Seigneux
  • Chantal Csajka
  • Jacques Fellay
  • Bruno Ledergerber
  • Philip E Tarr
View graph of relations

BACKGROUND: In human immunodeficiency virus (HIV), the relative contribution of genetic background, clinical risk factors, and antiretrovirals to chronic kidney disease (CKD) is unknown.

METHODS: We applied a case-control design and performed genome-wide genotyping in white Swiss HIV Cohort participants with normal baseline estimated glomerular filtration rate (eGFR >90 mL/minute/1.73 m2). Univariable and multivariable CKD odds ratios (ORs) were calculated based on the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) score, which summarizes clinical CKD risk factors, and a polygenic risk score that summarizes genetic information from 86 613 single-nucleotide polymorphisms.

RESULTS: We included 743 cases with confirmed eGFR drop to <60 mL/minute/1.73 m2 (n = 144) or ≥25% eGFR drop to <90 mL/minute/1.73 m2 (n = 599), and 322 controls (eGFR drop <15%). Polygenic risk score and D:A:D score contributed to CKD. In multivariable analysis, CKD ORs were 2.13 (95% confidence interval [CI], 1.55-2.97) in participants in the fourth (most unfavorable) vs first (most favorable) genetic score quartile; 1.94 (95% CI, 1.37-2.65) in the fourth vs first D:A:D score quartile; and 2.98 (95% CI, 2.02-4.66), 1.70 (95% CI, 1.29-2.29), and 1.83 (95% CI, 1.45-2.40), per 5 years of exposure to atazanavir/ritonavir, lopinavir/ritonavir, and tenofovir disoproxil fumarate, respectively. Participants in the first genetic score quartile had no increased CKD risk, even if they were in the fourth D:A:D score quartile.

CONCLUSIONS: Genetic score increased CKD risk similar to clinical D:A:D score and potentially nephrotoxic antiretrovirals. Irrespective of D:A:D score, individuals with the most favorable genetic background may be protected against CKD.

Original languageEnglish
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume70
Issue number5
Pages (from-to)890-897
Number of pages8
ISSN1058-4838
DOIs
Publication statusPublished - 14 Feb 2020

ID: 59944482